Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06400173

Validation Of The Flemish Montreal Cognitive Assessment (MoCA) For Persons With Hearing Impairment

Status
Recruiting
Phase
Study type
Observational
Enrollment
450 (estimated)
Sponsor
University Ghent · Academic / Other
Sex
All
Age
45 Years – 80 Years
Healthy volunteers

Summary

The Montreal Cognitive Assessment (MoCA) is a screening test for detecting cognitive impairment that assesses several cognitive domains (attention and concentration, arithmetic and orientation, memory, etc.). The instructions as well as some test items of the MoCA are presented auditory (spoken). Consequently, performance on the MoCA may be co-dependent on hearing. Therefore, to rule out the possible negative influence of hearing loss on performance on the MoCA, a MoCA for individuals with hearing loss was recently developed. More specifically, the original MoCA was modified by providing the instructions audiovisually (spoken with visual support) as well as by replacing hearing-dependent items. Since replacing items may affect sensitivity and specificity, the MoCA for persons with hearing loss should be revalidated.

Conditions

Interventions

TypeNameDescription
BEHAVIORALCognitive screeningThe Dutch Montreal Cognitive Assessment for persons with hearing loss (MoCA-HI) is a modified version of the original MoCA test specifically designed for individuals with hearing loss. It includes adaptations such as visual aids to accommodate for hearing loss, ensuring fair assessment of cognitive abilities in this population.
BEHAVIORALAudiological AssessmentFour audiological tests are included in the audiological assessment 1. Tympanometry to assss the middle ear status 2. Pure-tone audiometry with headphone to evaluate the hearing thresholds 3. Speech audiometry in free field to assess the ability to understand spoken words in the presence of background noise 4. The hAVICOP questionnaire to assess the hearing-related quality of life

Timeline

Start date
2023-09-01
Primary completion
2025-12-31
Completion
2025-12-31
First posted
2024-05-06
Last updated
2024-05-06

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT06400173. Inclusion in this directory is not an endorsement.